Journal of the National Cancer Institute
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.
Noor Wortelboer, Seamus Kent, Hedwig M Blommestein, Annemiek van Ommen-Nijhof, Vincent van der Noort, Esther van den Pol, Cristina Guerrero Páez, Aart Beeker, Karin Beelen, Lisanne C Hamming, Joan B Heijns, Aafke H Honkoop, Paul C de Jong, Quirine C van Rossum-Schornagel, Christa van Schaik- van de Mheen
Published: 202510.1093/jnci/djaf334
Abstract
BACKGROUND: The SONIA trial demonstrated that addition of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) to first-line endocrine therapy (aromatase-inhibitor) was not superior in terms of progression-free survival after two treatment lines (PFS…
Preview only. Read the full abstract at the source